The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth.Recently,inhibition of mTOR complex 1 (mTORC1) with rapamycin has also been shown in both clinical and experimental studies to have beneficial effects in diabetic nephropathy and other kidney diseases including autosomal dominant polycystic kidney disease and renal cell carcinoma.